EXTON, Pa. -- (BUSINESS WIRE) -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for difficult-to-treat skin diseases and conditions where autologous fibroblasts with or without genetic modification can play a key role in addressing unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, Fibrocell Science, will present at the Rodman & Renshaw 15th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
Mr. Pernock will provide a corporate overview during the live presentation on Tuesday, September 10 at 11:15 a.m. and will be joined by newly appointed Chief Financial Officer, Greg Weaver.
If you are an institutional investor and would like to attend the Fibrocell Science presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Mr. Pernock.
|Event: 15th Annual Rodman & Renshaw Global Investment Conference|
|Date and Time: Tuesday, September 10, 2013 at 11:15 a.m. ET|
|Location: 7th Floor, Room 7.03 of the Millennium Broadway Hotel in New York City|
The presentation will be webcast live. To access the webcast, please visit www.rodm.com or use the direct link, wsw.com/webcast/rrshq23/FCSC. The presentation will also be posted in the “Events and Presentations” section of the Fibrocell Science website at www.fibrocellscience.com/investors/events-and-presentation/. The webcast replay will be available for 90 days following the live presentation.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT: FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.
About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.